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the blood flow,4 but also in other ultrasonographic appli-
cations.5 The principle of echo-contrast enhancement is
based on the physical property of microbubbles of a few
micrometers in diameter to resonate at a frequency that
happens to be 3 to 10 MHz, which is typically used for
ultrasound diagnostics. This resonance causes a much
larger scattering cross-section, resulting in a much higher
reflectance of the ultrasound beam.
The ideal contrast agent should be nontoxic, ready to
be used intravenously, capable of crossing the pulmonary
capillaries, and stable enough to allow sufficient Doppler
and gray-scale ultrasound enhancement. Depending on the
bubble structure the early developed agents were short-
lived, amounting to a few seconds (eg, shaken saline solu-
tion, indocyanin green, or Echovist, Schering, Berlin,
Germany6). Subsequently, air-based bubbles were devel-
oped and were stabilized by albumin or a saccharide (galac-
tose) to survive for detection in the left heart (Albunex or
Infoson, Nycomed, Oslo, Norway7) or the blood pool
(Levovist, Schering, Berlin, Germany8), but with a still-
limited echogenicity. The most recent generation has a
high and prolonged reflectivity suitable for peripheral cir-
culation investigation, either by use of a low-soluble phase-
change agent (dodecafluoropentane; Echogen, Sonus,
Bothell, Wash9) or sulphur hexafluoride (SF6)-filled
microbubbles (SonoVue10; Bracco Diagnostics Inc,
Princeton NJ), which are found to be innocuous and
hardly antigenic because they contain no protein.
Literature data about the clinical usefulness of the
third-generation contrast-enhancing agents for duplex
In the diagnosis of arterial disease of the lower limbs,
color-flow duplex ultrasonography plays a central role to
assess the presence and severity of stenoses and their treat-
ment options because it yields a combination of anatomic
and hemodynamic information. Although angiography is
still widely used as a routine diagnostic procedure, duplex
scanning without angiography is becoming increasingly
popular for preoperative workup.1,2 On the other hand
this diagnostic potential is limited in that it is operator and
apparatus dependent and may be compromised as a result
of anatomic barriers, such as the adductor canal, the
tibioperoneal bifurcation, or pathologic conditions, such
as a low-flow state, especially in multilevel disease condi-
tions or calcifications of the arterial wall.
During the last 15 years, echo-enhancing particles have
been developed in an attempt to overcome many of these
drawbacks, whereas the concept was discovered many years
before.3 These particles can either be microbubbles or
(even tissue-targeted) agents that enhance visualization of
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Objective: This was a dose-finding and effectiveness study of a newly developed contrast-enhancing agent, sulphur hexa-
fluoride (SF6), in patients with peripheral arterial disease in whom the therapeutic policy could not be established on
the basis of standard color-flow duplex scanning of the leg arteries.
Methods: In this open-label, randomized, dose-ranging, crossover design, 14 patients in whom the assessment of vessel
patency was difficult because of poor visibility (low-flow state) or extensive wall calcifications were studied. Contrast-
enhanced duplex scanning was performed on the upper leg (n = 4), lower leg (n = 6), or pedal (n = 4) arteries after
intravenous injection of four different dosages of SF6. The results were compared with those from selective angiogra-
phy of the vessel of interest. Contrast duration and agreement about the diagnosis and the confidence in the diagnosis
were obtained before and after administration of the contrast agent.
Results: No adverse effects of the contrast agent were seen. Overall agreement was reasonable with regard to vessel
patency between contrast-enhanced duplex scanning and angiography (71%). Nine of 14 vessels (64%) appeared open
when contrast was applied. In four cases this could not be confirmed by angiography; in two of these cases this was
due to the presence of collateral vessels. All vessels that appeared occluded with the contrast agent were also occluded
on the angiogram. The confidence in the diagnosis increased from 56% to 91% after contrast administration (P <
.0001).
Conclusion: SF6-enhanced color-flow duplex scanning is a safe method that may improve the assessment of the patency
of leg arteries, particularly in low-flow states. The visualization of collateral vessles during (enhanced) duplex scanning
may be misleading because they may be regarded as the vessel of interest. (J Vasc Surg 2002;35:392-6.)
ultrasonography of the leg arteries are scanty,11 except for
some safety and dose-finding studies.12-15 In this study we
investigated the value of SF6 to enhance routine duplex
visualization of the leg arteries in patients with a diagnos-
tic dilemma. In particular, we investigated the dosage
needed for optimal visualization, the duration of useful
contrast enhancement, and the possibility to reach a defi-
nite diagnosis.
PATIENTS AND METHODS
Patients. From the patients referred to the vascular
laboratory for routine duplex investigation, 14 noncon-
secutive patients were included in this study in whom
uncertainty existed with regard to the patency of a certain
part of the leg arteries that could not be visualized con-
clusively by means of unenhanced duplex scanning. This
can be caused by atherosclerotic vessel wall calcifications,
a low-flow state, or the localization of the vessel (eg, the
tibioperoneal trunk, which generally runs perpendicular to
the transducer). The vessels were selected either because
they were the target vessel for a vascular intervention
(bypass grafting or angioplasty) or to be informed about
the runoff distal to the previewed anastomosis.
Excluded were patients with severe cardiac insuffi-
ciency or arrhythmia or a myocardial infarction during the
previous 14 days, a critical or unstable illness, or those
who received any other contrast medium within 48 hours
before or 24 hours after this investigation. These exclusion
criteria were formulated to avoid any risk of jeopardizing
the patients’ condition because of the administration of
the contrast agent, which also had a dose-finding purpose.
All patients were included after providing written
informed consent.
The mean age of the six men and eight women was 69
years (range 45 to 83 years). Eight patients had ischemic
ulcerations, five had intermittent claudication, and one
had ischemic rest pain. Six patients had hypertension, two
had diabetes mellitus, and one had hypercholesterolemia.
Methods. This study had an open-label, randomized,
dose-ranging, crossover design. It was part of a larger
European multicenter phase II/III trial designed to inves-
tigate the safety and diagnostic potential of SF6 in different
vascular beds, ranging from intracranial and extracranial,
abdominal to peripheral arteries, as well as the portal cir-
culation.15 In our center the protocol was directed specifi-
cally to the leg arteries. Randomization was performed by
the supplier of the contrast agent (Bracco Research) before
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the vials were dispatched to our hospital. The order in
which the four dosages were to be administered in each
patient was given in the package sent for each patient.
Routine color-flow duplex scanning was performed ini-
tially without contrast enhancement to localize the artery of
interest. The contrast medium was administered in four
dosages: 0.3, 0.6, 1.2, and 2.4 mL of 5 mg/mL SF6. A dose
of 1.2 mL equals about 1 to 5 × 108 microspheres/mL and
0.02 mL/kg in a person weighing 60 kg. To scan the ves-
sels we used a Hewlett Packard Sonos 2000 duplex scanner
(Agilent Technologies, Andover, Mass) with a 5- or 7.5-
MHz linear probe. We refrained from using harmonic
imaging or power duplex scanning, because this is the stan-
dard practice in our vascular laboratory. Duplex scanning
was performed by an experienced vascular technologist who
was blinded to the dosage of the contrast.
As a reference standard, selective angiography of the
leg arteries down to the pedal arch was performed by ante-
grade puncture of the common femoral artery within 6
weeks before or after the duplex investigation, but not less
than 48 hours before or 24 hours after the contrast admin-
istration. The study protocol was approved by the hospital
medical ethical committee.
Investigation protocol. The patient was placed in a
decubitus position. Brachial blood pressure was moni-
tored continuously by use of a Dinamap blood pressure
monitor (Criticon, Dinamap Plus, Tampa, Fla). During
the baseline duplex investigation of the assigned vessel of
interest, the color-flow and spectral Doppler gain was set
to obtain optimal images and Doppler spectra. Then the
gain was reduced to the lowest level that still allowed visu-
alization of the region of interest to anticipate the contrast
enhancement. This gain setting was kept throughout the
whole investigation to enable comparison of the effect of
the four dosages to be administered.
SF6 was provided in a vial containing 25 mg
lyophilized, sterile powder to which 5 mL saline solution
needs to be added followed by hand agitation.
Subsequently, the four prepared contrast boluses were
administered in random order and in 20 seconds via a 20-
gauge intravenous catheter in a large antecubital vein. The
catheter was flushed with 5 mL saline solution. Between
these administrations at least a 10-minute interval was
taken to ensure total disappearance of the contrast
enhancement from the previous administration. The
investigator was unaware of the dose given. After each
bolus, color-flow duplex imaging was used to await the
Table I. Median time parameters (interquartile ranges) of echo contrast enhancement for each dose given
Parameter 0.3 mL 0.6 mL 1.2 mL 2.4 mL P value*
Appearance time (s) 38 (34-53) 37 (29-57) 36 (32-51) 35 (27-49) .037
Enhancement duration (s) 197 (111-292) 234 (127-483) 351 (183-459) 439 (324-497) .014
Duration of clinically useful enhancement (s) 92 (21-159) 111 (78-251) 147 (70-263) 164 (106-247) .063
Artifact duration (s) 115 (17-198) 122 (24-366) 146 (30-334) 241 (74-468) .011
*Friedman test.
appearance of the contrast, and specific velocity measure-
ments were performed by use of the Doppler spectral
mode at a 60-degree beam-to-vessel angle. The images
obtained were recorded on videotapes for offline analysis.
Analysis. To avoid interpretation bias, angiography
was performed after the enhanced duplex investigation,
and each was conducted by independent investigators and
interpreted blindly. From the video recordings, which
were interpreted by readers who did not perform the
duplex scanning, the appearance time and duration of the
contrast enhancement was measured in seconds, as well as
the duration of artifacts that compromised the image
analysis, such as blooming (presence of color outside the
vessel wall) or saturation (noisy Doppler spectrum with
velocities obviously over the actual velocity), and the esti-
mated duration of clinically useful contrast enhancement.
The median differences as found among the four dosages
were investigated statistically by use of the nonparametric
Friedman test.
The diagnostic confidence was a parameter used to
assess the additional effect of the contrast agent.16 It was
estimated by the independent readers who interpreted the
video recordings by means of a visual analog scale (rang-
ing from 0, “completely unsure,” to 100, “completely
sure”). These diagnostic confidence scores were compared
between the baseline and enhanced duplex scanning. The
final diagnosis was then compared with the angiographic
results. Statistical analysis of these differences was per-
formed by use of the paired Student t test.
RESULTS
No patients were excluded because of any recent heart
or critical disease. The administration of another contrast
agent shortly before or after SF6 could be avoided. The
vessels of interest were the superficial femoral artery in
one, the popliteal artery in three, the tibioperoneal trunk
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in three, the peroneal artery in two, the posterior tibial
artery in one, the dorsal pedal artery in one, and the plan-
tar artery in three cases. No adverse effects or changes in
blood pressure were observed during the contrast admin-
istrations. In most cases a low-flow state (36%) or wall cal-
cifications (29%) hampered accurate assessment of local
blood flow in the unenhanced duplex investigations.
The different time parameters after administration of
the contrast are summarized in Table I. The contrast
appeared slightly but significantly quicker when a higher
dose was given. The duration of the contrast enhancement
was significantly dose-related, as well as the duration of
the artifacts. The clinically useful enhancement did not
increase above a dose of 1.2 mL.
Table II shows the duplex and angiographic results in
each individual patient. With contrast enhancement, nine
of the 14 vessels investigated were found to be open; that
is, 64% of the inconclusive duplex results appeared to be
resolved. All vessels that appeared occluded by use of con-
trast-enhanced duplex scanning were also occluded on
the angiogram. Moreover, in all patients the confidence in
providing an answer to the diagnostic question increased
from 56% to 91% (P < .0001). Angiography found four of
13 vessels to be open, whereas in one patient the
angiogram was inconclusive. Hence, in four cases the
enhanced duplex scanning and angiography results were
contradictory. In two of those cases the enhanced duplex
scan appeared to have appreciated a collateral vessel. In
the third case duplex scanning found the tibioperoneal
trunk to be open, which was not confirmed by angiogra-
phy, and in the fourth case the duplex scan found the
plantar artery open, whereas angiography could not visu-
alize the vessels distal to the posterior tibial artery. These
data would result in a sensitivity and specificity for the
unenhanced duplex scan of 89% (95% confidence interval
[CI], 72%-100%) and 50% (95% CI, 23%-77%), and for
Table II. Data on investigated vessels and diagnostic outcomes (diagnostic confidence in %) in each individual patient
Unenhanced duplex Enhanced duplex
Patient number Artery investigated scanning result scanning result Angiography result
1 Popliteal Occluded (80%) Open (80%) Open
2 Popliteal Occluded (70%) Occluded (90%) Occluded
3 Peroneal Open (40%) Open (100%) Open
4 Peroneal Occluded (50%) Occluded (90%) Occluded*
5 Dorsal pedal Occluded (70%) Occluded (100%) Occluded
6 Common plantar Occluded (50%) Open (100%) Inconclusive
7 Posterior tibial Open (30%) Open (90%) Open
8 Tibioperoneal trunk Open (20%) Open (95%) Open
9 Superficial femoral Occluded (80%) Occluded (100%) Occluded
10 Common plantar Occluded (65%) Open (90%) Occluded†
11 Common plantar Open (30%) Open (90%) Occluded‡
12 Tibioperoneal trunk Occluded (65%) Occluded (95%) Occluded
13 Tibioperoneal trunk Occluded (60%) Open (70%) Occluded
14 Popliteal Occluded (75%) Open (90%) Occluded§
*Collateral bridging observed by all techniques.
†Angiography showed occluded posterior tibial artery without visualizing plantar arteries.
‡Collateral vessel mistaken for plantar artery with enhanced duplex scanning.
§Collateral vessel mistaken for popliteal artery with enhanced duplex scanning.
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the enhanced duplex scan of 56% (29%-83%) and 100%
(100%-100%), respectively.
DISCUSSION
Nowadays, duplex investigation of the lower limb is
part of the standard workup to assess the treatment
options in severe leg ischemia. For this purpose visualiza-
tion of the vessel and velocity measurements are prerequi-
sites. Difficulties arise in cases of vessel wall calcifications
or low-flow states in multilevel disease. In the diagnosis of
peripheral arterial disease of the legs, this study showed
that contrast enhancement with SF6 appears a safe and
possibly useful additional tool when routine duplex scan-
ning is inconclusive, particularly when anatomic or patho-
physiological conditions interfere with visualization of the
vessel. Because the aim of this study was not primarily to
evaluate the usefulness of SF6 in choosing the best treat-
ment for the patient, we cannot conclude at this stage
whether SF6 may prove a useful diagnostic adjunct.
When the vessel of interest is occluded, even when
contrast enhancement is used, further angiographic con-
firmation may be superfluous. In spite of being generally
considered as reference standard, arteriography per se has
its own limitations and may not always be in agreement
with intraoperative (angiographic) findings. However, in
this study we tried not to bias our results toward duplex
scanning and accepted the results of angiography to be
correct in all cases. The data concerning the diagnostic
accuracy of (un)enhanced duplex scanning as compared
with angiography are difficult to interpret, because of the
uncertainty by definition of the unenhanced duplex
results, the wide 95% confidence intervals, and because
one could question angiography as the gold standard.
An intravenous bolus dosage of 1.2 mL, that is, 6 mg
of the contrast agent, appeared optimal for the visualiza-
tion of the leg arteries. The duration of the contrast
enhancement was about 6 minutes, of which 2.5 minutes
was clinically useful. This is enough to assess vessel patency
or severity of a stenosis. The fixed gain setting as used in
this study probably reduced the clinically useful period of
contrast enhancement. The enhancement duration was
also quite comparable with that in transcranial applica-
tions.17 Comparison of the intensity of the contrast
enhancement, however, may be hampered by different
Doppler settings.18 When longer observation periods are
required, continuous infusion of contrast agents has been
shown to be a useful alternative.19
On the other hand, drawbacks of using an ultrasound
contrast agent are its invasive nature and the diagnostic
difficulties it may cause by further facilitating the visual-
ization of collateral vessels. This is already a common pit-
fall in standard duplex scanning, causing false-positive
results with regard to the patency of the vessel of interest.
This explained most of the discrepancies with the angio-
graphic results. Finding the accompanying vein or an
eventual connection with the axial artery while tracing the
collateral vessels would have been of assistance in identify-
ing the axial artery. However, this can be an awkward task.
In these circumstances, especially in the crural arteries,
additional angiography is still mandatory.1
In this study the observed contrast artifacts blooming
and saturation did not interfere substantially with the
assessment of vessel patency. This was probably influenced
by the fixed low gain setting. Yet these artifacts may com-
promise velocity measurements when the severity of
stenoses needs to be assessed. Continuous contrast infu-
sion might help in overcoming these artifacts. In the near
future several other applications of ultrasound contrast
enhancement will become available when other genera-
tions of contrast agents become available, such as gray-
scale enhancement, investigation of parenchymatous
organs, and demonstrating receptor sites or specific mole-
cules by targeted agents, which may open other interest-
ing therapeutic routes.20
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The Lifeline Registry
The Lifeline Foundation® was established to actively
support initiatives that will result in the treatment, preven-
tion, and cure of vascular disease. The Lifeline Foundation
is the nonprofit research arm of the American Association
for Vascular Surgery and the Society for Vascular Surgery.
The Lifeline Registry of Endovascular Aneurysm
Repair provides information on endovascular repair by
gathering long-term data on the safety and efficacy of
endovascular grafts in patients that received investigational
or commercial devices for abdominal aortic aneurysms.
Benefits of The Lifeline Registry
By participating in the Lifeline Registry of Endo-
vascular Repair, clinical sites will be able to:
• Enter, store, and access data in an existing, user-
friendly data management system; 
• Improve clinical management of patient follow-up
through tracking patient progress over time;
• Receive periodic reports to demonstrate the progress
of patients compared with an aggregate of an 
equivalent patient population;
• Generate real-time data reports of the site’s own data
(for example: aneurysm change over time, age, gen-
der, race distribution, adverse event tracking);
• Store and compare diagnostic images over time;
• Maintain secure and confidential record keeping
through use of password access;
• Obtain free technical support.
Contact The Lifeline Registry
To learn more about The Lifeline Registry please log on
to www.lifelineregistry.org
For queries regarding The Lifeline Registry and how to
join, please contact: New England Research Institutes, Inc
Telephone (800) 775-6374, ext 365 
E-mail: lifeline@neri.org
LIFELINE REGISTRY OF ENDOVASCULAR ANEURYSM REPAIR
